Guide to buying Vertex Pharmaceuticals stock in Canada

Vertex Pharmaceuticals is a biotechnology business based in the US. Vertex Pharmaceuticals stocks (VRTX) are listed on the NASDAQ, and all prices are listed in US Dollars.

At its last market close, Vertex Pharmaceuticals stock price was $549.04, which is an increase of 1.67% over the previous week. Vertex Pharmaceuticals employs 6,400 staff and has a trailing 12-month revenue of around $12.6 billion.

Keep reading to see up-to-date Vertex Pharmaceuticals stock price and performance data, along with a step-by-step guide for how to buy Vertex Pharmaceuticals stock in Canada.

Vertex Pharmaceuticals (VRTX) stock summary

Company stock name	Vertex Pharmaceuticals Inc
Stock ticker symbol	VRTX
Exchange	NASDAQ
Open	$535.63
High	$550.77
Low	$527.38
Close	$549.04
Adjusted closing	$549.04
Volume The number of stocks traded during the day	1,810,265
52-week stock price range	$403.16 – $560.25
Where to buy Vertex Pharmaceuticals stock	Buy on Questrade

The values in this table are accurate as of the market close on November 3, 2026, and all amounts are in USD.

Can I buy Vertex Pharmaceuticals stock in Canada?

Yes, you can buy Vertex Pharmaceuticals stock in Canada. You simply need to open a brokerage account with an online trading platform that supports stocks on the NASDAQ exchange. Platforms like Questrade and Wealthsimple will allow you to directly buy Vertex Pharmaceuticals stock from within Canada.

Dive deeper: Detailed guide on how to buy stocks in Canada

Our top picks for where to buy Vertex Pharmaceuticals stock

Vertex Pharmaceuticals stock chart (NASDAQ: VRTX)

This chart tracks Vertex Pharmaceuticals stock price performance over time.

Vertex Pharmaceuticals stock price

Vertex Pharmaceuticals's stock price at the last available market close was $549.04 (as of November 3, 2026). For comparison, seven days ago Vertex Pharmaceuticals's stock price was $523.93. A full 30 days ago it was $504.73, and a year ago it was $419.89.

Is Vertex Pharmaceuticals stock a buy or sell right now?

The technical analysis gauge above shows real-time buy or sell ratings and analysis for Vertex Pharmaceuticals stock based on your selected timeframe. It uses three widely followed indicators—moving averages, oscillators and pivots—but this does not represent investment advice or a guarantee of success. Finder may not concur with these signals and accepts no responsibility for the performance of your stocks.

Can I buy Vertex Pharmaceuticals stock on the TSX?

No, you cannot buy Vertex Pharmaceuticals stock on the TSX because Vertex Pharmaceuticals stock is not listed on the TSX. Instead, Vertex Pharmaceuticals stock is listed on the NASDAQ under the symbol "VRTX."

That said, if you're wondering how to invest in Vertex Pharmaceuticals stock in Canada, you still have the option to do so by opening a trading account with a Canadian brokerage that gives you access to NASDAQ, like Questrade or Wealthsimple.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Vertex Pharmaceuticals stock dividends

Vertex Pharmaceuticals is not expected to pay a dividend over the next 12 months.

Vertex Pharmaceuticals stock performance metrics

Here are some common key metrics for Vertex Pharmaceuticals stock that analysts often use to help gauge a stock's value—P/E ratio, PEG ratio and EBITDA.

• Vertex Pharmaceuticals's P/E ratio

  Vertex Pharmaceuticals's current share price divided by its per-share earnings (EPS) over the past 12 months gives a trailing price/earnings (P/E) ratio of roughly 36x.

  That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

• Vertex Pharmaceuticals's PEG ratio

  Vertex Pharmaceuticals's price/earnings-to-growth (PEG) ratio comes out to about 2.1599.

  The PEG ratio provides a broader view than the P/E ratio alone, as it factors in Vertex Pharmaceuticals's expected earnings growth.

• Vertex Pharmaceuticals's EBITDA

  Vertex Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortization) is $5.1 billion.

Has Vertex Pharmaceuticals stock ever split?

Vertex Pharmaceuticals's stocks were split on a 2:1 basis on August 23, 2000. So, if you had owned 1 share the day before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals stocks, just the quantity.

However, indirectly, the new 100% higher stock price could have impacted the market appetite for Vertex Pharmaceuticals stocks, which in turn could have impacted Vertex Pharmaceuticals's stock price.

How volatile is Vertex Pharmaceuticals stock?

Over the last 12 months, Vertex Pharmaceuticals's stocks price has ranged from $403.16 to as high as $560.25. Vertex Pharmaceuticals's beta measurement of stock volatility is 0.28. For comparison, the market (NASDAQ) average beta is 1. This would suggest that Vertex Pharmaceuticals's stocks are less volatile than average (on this exchange).

Some analysists use "beta" to gauge a stock's volatility. Beta is a popular way to measure a stocks volatility in relation to the market. Here is a breakdown of Vertex Pharmaceuticals's beta stock volatility rating.

Vertex Pharmaceuticals Inc company and revenue performance

Market Capitalization The total market value of Vertex Pharmaceuticals's outstanding shares	$136.9 billion
Gross profit (TTM)	$6.9 billion
Operating margin (TTM)	38.06%
Profit margin	35.00%
Revenue (TTM)	$12.6 billion
Return on assets (TTM)	11.93%
Return on equity (TTM)	23.54%
Earnings per share (TTM)	$14.91
50-day moving stock price average The average share price over the last 50 days	$522.84
200-day moving stock price average The average share price over the last 200 days	$478.67

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 3, 2026.

Vertex Pharmaceuticals company profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.

In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics.

Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions.

• Common company-related questions about Vertex Pharmaceuticals

  What percentage of Vertex Pharmaceuticals is owned by insiders or institutions?
  Currently 0.212% of Vertex Pharmaceuticals stocks are held by insiders and 98.169% by institutions.

  How many people work for Vertex Pharmaceuticals?
  Latest data suggests 6,400 work at Vertex Pharmaceuticals.

  When does the fiscal year end for Vertex Pharmaceuticals?
  Vertex Pharmaceuticals's fiscal year ends in December.

  Where is Vertex Pharmaceuticals based?
  Vertex Pharmaceuticals's address is: 50 Northern Avenue, Boston, MA, United States, 02210

Compare trading platforms to buy Vertex Pharmaceuticals stock

Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.

Related: Compare the best stock trading platforms in Canada

Do I have to pay tax on gains from Vertex Pharmaceuticals stock sales in Canada?

Yes, you'll need to pay taxes in Canada on investment income, which includes any profit from selling Vertex Pharmaceuticals stock. The CRA taxes investment income from stocks in Canada based on three main factors:

1. Investment income. Investment income includes money earned from interest, dividends or capital gains, which may affect how much you have to pay in taxes on stock sales in Canada.
2. Investor type. Your investment income will be taxed differently depending on whether you're a regular investor or a day trader (which means you buy and trade stocks on a daily basis as your primary form of income).
3. Tax bracket. The higher your tax bracket, the more you'll pay on income from stock sales. Your tax bracket depends on your gross income (minus deductions).

You can learn more about the tax implications of selling stocks in Canada here.

Frequently asked questions about Vertex Pharmaceuticals stock

• Can I buy Vertex Pharmaceuticals stock directly as a Canadian investor?

  Yes, Canadian investors can buy Vertex Pharmaceuticals stock directly through various online brokerage platforms available in Canada. You can compare trading platform options and fees for buying Vertex Pharmaceuticals stock in our table here.

• How much is Vertex Pharmaceuticals stock worth?

  As of the last market close (on November 3, 2026), Vertex Pharmaceuticals stock is worth $549.04 per share.

• Can Canadians buy American stocks?

  Yes, Canadians can buy American stocks through Canadian trading platforms that give access to American stock exchanges such as the NYSE and Nasdaq. The good news is that most Canadian brokerage platforms, like Questrade, Interactive Brokers, Moomoo and Wealthsimple, give access to US exchanges. Read our full guide on how to buy US stocks in Canada to learn more.

• Can I buy fractional shares of Vertex Pharmaceuticals stock?

  Yes, it may be possible to buy fractional shares of Vertex Pharmaceuticals stock depending on the trading platform you're signed up with. Fractional shares can allow you to invest in Vertex Pharmaceuticals stock even when you can't afford its full share price. You can read our full guide to how fractional shares work to learn more.

  The table below shows trading apps in Canada that offer fractional shares:

  4 of 4 results

  Finder Score	Available Asset Types	Account Types	Stock Trading Fee	Monthly Account Fee
  Promoted 9.6 Excellent Questrade	9.6 Excellent	Stocks, Bonds, Options, Mutual Funds, Index Funds, ETFs, Forex, GICs, Precious Metals, IPOs	RRSP, RESP, RRIF, TFSA, Personal, Joint, FHSA, Margin	$0	$0	Get $50 cash back when you open a Questrade self-directed investing account through Finder. T&Cs apply.	Go to site View details Compare product selection Compare	loading
  8.6 Great Wealthsimple Investing	8.6 Great	Stocks, Options, ETFs, Cryptocurrency	RRSP, RESP, RRIF, TFSA, Personal, FHSA, Margin	$0	$0	Get a 1% match cash bonus on eligible $25,000+ transfers from other financial institutions to your Wealthsimple Self-directed Investing and Managed Investing accounts. T&Cs apply.	Go to site View details Compare product selection Compare	loading
  9.4 Excellent Interactive Brokers	9.4 Excellent	Stocks, Bonds, Options, Index Funds, ETFs, Forex, Currencies, Futures	RRSP, TFSA, Personal, Joint, Business, FHSA, Margin	Min $1.00, Max 0.5%	$0	Continue View details Compare product selection Compare	loading
  8.6 Great Moomoo	8.6 Great	Stocks, Options, ETFs	RRSP, TFSA, Personal, Margin	$1.49/stock	$0	Continue View details Compare product selection Compare	loading

  loading

  Load More

  Showing 4 of 4 results

  Compare other products

  Looking for other options? Check out these similar products.

  How we picked these

  Finder Score for stock trading platforms

  To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.

  Read the full methodology

Related: New to stock trading? Compare brokers and get tips for investing.

Important information: Powered by Finder.com. This information is general in nature and is no substitute for professional advice. It does not take into account your personal situation. This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for most investors. You do not own or have any interest in the underlying asset. Capital is at risk, including the risk of losing more than the amount originally put in, market volatility and liquidity risks. Past performance is no guarantee of future results. Tax on profits may apply. Consider the Product Disclosure Statement and Target Market Determination for the product on the provider's website. Consider your own circumstances, including whether you can afford to take the high risk of losing your money and possess the relevant experience and knowledge. We recommend that you obtain independent advice from a suitably licensed financial advisor before making any trades.